Earnings summaries and quarterly performance for Tectonic Therapeutic.
Executive leadership at Tectonic Therapeutic.
Board of directors at Tectonic Therapeutic.
Research analysts covering Tectonic Therapeutic.
Recent press releases and 8-K filings for TECX.
Tectonic Provides APEX Study Update and Financial Runway
TECX
Guidance Update
New Projects/Investments
- Tectonic's APEX study enrollment is on track for its end-of-year recruitment goal, and the company expects to narrow guidance on enrollment completion by the end of Q1 2026.
- The Data Safety Monitoring Committee (DSMB) for the APEX study reported no safety signal as of its last meeting at the end of September.
- Tectonic's TX45 is differentiated from competitors by its longer half-life, which is expected to enable monthly dosing compared to Lilly's weekly and AstraZeneca's every other week dosing.
- The company plans to submit regulatory documents for its TX2100 healthy volunteer study around December 2, 2025, with the study anticipated to start in early 2026.
- Tectonic has a cash runway into Q4 2028, with approximately $268 million in cash at its last quarterly earnings.
Dec 2, 2025, 8:30 PM
Tectonic Provides Update on APEX Study Enrollment, TX2100 Development, and Cash Runway
TECX
Guidance Update
New Projects/Investments
- Tectonic expects to narrow guidance on APEX study enrollment completion by the end of Q1 2026, having met internal recruitment objectives for mid-year and being on track for end-of-year goals. The study's Data Safety Monitoring Board (DSMB) reported no safety signal in late September and recommended the continuous plan.
- The APEX study is now exclusively recruiting patients with a PVR greater than three, a subset representing 70% of the total population, based on the hypothesis of greater benefit in this group.
- Tectonic's TX45 is differentiated from competitors by its longer half-life, which is expected to enable monthly dosing, in contrast to weekly for Lilly's and every other week for AstraZeneca's relaxin fusions.
- The company plans to submit regulatory documents for TX2100 today or tomorrow and anticipates starting a healthy volunteer study in early 2026 (1Q).
- Tectonic reports a cash runway extending into Q4 2028, with approximately $268 million in cash at its last quarterly earnings.
Dec 2, 2025, 8:30 PM
Tectonic Provides Update on APEX Study Progress and Financials
TECX
Guidance Update
New Projects/Investments
Financials
- Tectonic (TECX) is on track to meet its end-of-year recruitment goal for the APEX study and expects to narrow guidance on enrollment completion by the end of Q1 2026.
- The Data Safety Monitoring Committee (DSMB) for the APEX study reported no safety signal at its last meeting in late September, recommending continuation of the plan.
- The APEX study has completed enrollment for patients with PVR less than three and is now only recruiting patients with a PVR greater than three, which represents 70% of the total population.
- Tectonic's TX45 has a longer half-life compared to competitors, potentially enabling monthly dosing. The company also reported a cash runway into Q4 2028 with approximately $268 million in cash at its last quarterly earnings.
Dec 2, 2025, 8:30 PM
Tectonic Therapeutic Announces Q3 2025 Financial Results and Business Highlights
TECX
Earnings
New Projects/Investments
Guidance Update
- Tectonic Therapeutic, Inc. reported cash and cash equivalents of $268.4 million as of September 30, 2025, with an anticipated cash runway into Q4 2028.
- For the three months ended September 30, 2025, the company recorded a net loss of $19.0 million, compared to a net loss of $17.7 million for the same period in 2024.
- Research and development expenses were $16.9 million for Q3 2025, an increase from $14.3 million in Q3 2024, primarily due to the discovery, development, and manufacturing of TX2100 and increased employee-related expenses.
- The company announced positive topline data from Part B of the TX45 Phase 1b trial and expects to initiate the TX2100 Phase 1 clinical trial in Q1 2026.
- The TX45 PH-ILD Phase 2 clinical trial is planned to initiate in 2026, and topline results for the ongoing TX45 APEX Phase 2 clinical trial are also expected in 2026.
Nov 6, 2025, 9:15 PM
Tectonic Therapeutic Announces Positive Phase 1b Part B Clinical Trial Data for TX45
TECX
New Projects/Investments
- Tectonic Therapeutic, Inc. (TECX) announced positive topline results from its Phase 1b Part B clinical trial for TX45 in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (PH-HFrEF) on October 29, 2025.
- A single intravenous dose of TX45 was well tolerated, showing no serious or severe adverse events.
- The trial demonstrated meaningful improvements in both left heart function and pulmonary hemodynamics, with a 29.2% decrease in Pulmonary Capillary Wedge Pressure (PCWP) and a 17.3% increase in Cardiac Output (CO).
- Echocardiography data at Day 29 indicated persistent improvements, including a 19.4% increase in Left Ventricular Ejection Fraction (LVEF) and a 20.3% improvement in Right Ventricular Fractional Area of Change (RVFAC).
- These findings support the potential expansion of TX45's addressable patient population to PH-HFrEF, with topline results from the ongoing APEX Phase 2 clinical trial expected in 2026.
Oct 29, 2025, 11:28 PM
TECX Reports Positive Phase 1B Part B Results for TX45 in PHFREF and Provides APEX Trial Update
TECX
New Projects/Investments
Guidance Update
- TECX announced positive top-line results from Part B of its Phase 1B clinical trial for TX45 in patients with pulmonary hypertension associated with reduced ejection fraction heart failure (PHFREF), demonstrating safety and significant improvements in hemodynamic measurements.
- Key hemodynamic improvements observed included a 29% decrease in pulmonary capillary wedge pressure, a 20% reduction in pulmonary vascular resistance (PVR) in the PVR ≥ 3 WU population, and a 17% increase in cardiac output.
- Echocardiographic data suggested sustained improvements in markers of left ventricular function, pulmonary hemodynamics, and right ventricular function up to 29 days post-dose after a single dose of TX45.
- The APEX Phase 2 clinical trial for TX45 is over 50% enrolled, with recruitment now limited to patients with PVR ≥ 3 WU; TECX plans to update and narrow guidance for the top-line readout by the end of Q1 2026.
- The company has a financial runway extending into the fourth quarter of 2028 and plans to initiate a study for TX45 in pulmonary hypertension associated with interstitial lung disease (PHILD) in 2026, while its TX2100 program for hereditary hemorrhagic telangiectasia remains on track to enter the clinic in Q1 2026.
Oct 29, 2025, 8:30 PM
TECX Reports Positive Results for TX45 in PH-HFrEF Study
TECX
New Projects/Investments
- TECX announced positive results from its TX45 Phase 1b (Part B) single-dose hemodynamic trial in patients with PH-HFrEF (Pulmonary Hypertension with Heart Failure with Reduced Ejection Fraction) in October 2025.
- The study observed that TX45 was well tolerated and demonstrated improvements in left ventricular function and pulmonary hemodynamics in PH-HFrEF patients, consistent with effects seen in a prior PH-HFpEF study.
- Key hemodynamic improvements included a -29.2% reduction in PCWP (pulmonary capillary wedge pressure) and a +17.3% increase in cardiac output (CO) across all participants (n=14).
- Echocardiographic results at Day 29 showed sustained improvements in markers of left ventricular and right ventricular function, including a +19.4% increase in LVEF (left ventricular ejection fraction).
- These results support further clinical investigation of TX45 in PH-HFrEF, potentially expanding its market opportunity, pending data from the ongoing APEX Phase 2 clinical trial.
Oct 29, 2025, 8:30 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more